TRIESENBERG, Liechtenstein--(BUSINESS WIRE)--Lysando AG – market leader in the field of antimicrobial proteins – has signed a general development agreement with Amicogen Inc., a publicly traded biotechnology company and CDMO headquartered in South Korea.
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.nThe deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando.
ResearchMoz in its recently published market study offers valuable regional as well as global insights related to the “Pharma-grade Synthetic Camphor ” market. As per the study, the global “Pharma-grade Synthetic Camphor ” market is estimated to reach a value of ~US$ XX Mn/Bn in 2019 and projected to grow at a CAGR of XX% over the forecast period, 2019-2029.